Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials

Carolyn Williamson, Chivonne Moodley, Craig A. Magaret, Elena Giorgi, Morgane Rolland, Dylan H. Westfall, Anna Yssel, Wenjie Deng, Raabya Rossenkhan, Nonhlanhla N. Mkhize, Lennie Chen, Hong Zhao, Tanmoy Bhattacharya, Alec Pankow, Ben Murrell, Talita York, Asanda Gwashu-Nyangiwe, Nonkululeko Ndabambi, Ruwayhida Thebus, Paula Marantz Cohen, Bronwen E. Lambson, Haajira Kaldine, Sinethemba Bhebhe, Michal Juraska, Hongjun Bai, Allan C. deCamp, James P. Ludwig, Cindy Molitor, Nicolas Beaume, David Matten, Yunda Huang, Lily Zhang, Daniel B. Reeves, Bryan T. Mayer, Shelly Karuna, John Hural, Lynn Morris, David C. Montefiori, Roger E. Bumgarner, Penny L. Moore, Paul T. Edlefsen, Srilatha Edupuganti, Nyaradzo Mgodi, M. Juliana McElrath, Myron S. Cohen, Lawrence Corey, Peter B. Gilbert, James I. MullinsbioRxiv 2025 · DOI

TL;DR

This study used deep sequencing to analyze HIV breakthrough infections in participants receiving the broadly neutralizing antibody VRC01. They found that a significant portion of infections involved multiple viral lineages, and that recombination played a key role in the evolution of VRC01-resistant viruses, highlighting the need for multi-target strategies in HIV prevention.

What Problem Does This Paper Address?

HIV remains a major global health challenge. Broadly neutralizing antibodies (bNAbs) like VRC01 show promise for preventing HIV acquisition, but their effectiveness can be influenced by the diversity of the virus at the time of infection and how the virus evolves under antibody pressure. Previous studies, often using less sensitive sequencing methods, suggested that most HIV infections are initiated by a single "founder" virus. However, the authors hypothesized that more sensitive techniques might reveal a higher frequency of "multilineage infections" (where multiple distinct viral strains establish infection simultaneously). Understanding this initial viral diversity and subsequent viral evolution is crucial for designing effective bNAb-based prevention strategies, especially since HIV is known for its rapid evolution and ability to develop resistance. This paper aims to characterize the genetic diversity of breakthrough HIV infections in the context of VRC01-mediated prevention trials, specifically looking at the impact of VRC01 on the initial viral population and its subsequent evolution.

Methods

The researchers employed long-read deep sequencing to analyze viral genomes from participants in the Antibody Mediated Prevention (AMP) trials. This technique allowed them to generate a large number of sequences (over 100,000 total) from two key HIV genomic regions: gag-Δpol (GP) and rev-env-Δnef (REN). They then used sophisticated bioinformatics pipelines to:

  • Classify sequences into Transmitted Founder Lineages (TFLs): This involved identifying distinct viral strains that successfully initiated infection.
  • Detect multilineage infections: They defined this as the presence of more than one TFL within a participant's infection.
  • Assess VRC01 sensitivity: They used pseudoviruses generated from representative viral sequences and measured their neutralization by VRC01 (quantified by IC80 values).
  • Analyze viral recombination: They identified instances where different viral sequences exchanged genetic material.
  • Estimate VRC01 concentrations: They used pharmacokinetic models to predict VRC01 levels at the estimated time of acquisition.

The use of deep sequencing is a key advancement here, offering much higher sensitivity than traditional methods for detecting rare viral variants.

Datasets

The study utilized data from the Antibody Mediated Prevention (AMP) trials, specifically:

  • HVTN 703/HPTN 081 (Africa trial): Enrolled women at high risk of HIV acquisition.
  • HVTN 704/HPTN 085 (Americas trial): Enrolled men who have sex with men and transgender individuals at high risk of HIV acquisition.

Participants in these trials received either VRC01 (at 10 mg/kg or 30 mg/kg doses) or a placebo, every eight weeks. The study analyzed viral sequences from 172 participants who acquired HIV during the trials.

Key Insights and Ideas

  • The "acquisition bottleneck" might be wider than previously thought: While the study acknowledges that only a few virions typically establish infection, their high-sensitivity sequencing revealed a surprisingly high frequency of multilineage infections, suggesting that multiple founder viruses can indeed establish infection.
  • VRC01's impact is complex: While VRC01 showed protective efficacy against susceptible strains, it didn't completely prevent infection by all strains. The antibody appears to exert selective pressure, influencing which viral variants persist and evolve.
  • Recombination is a major player in viral evolution under pressure: The study highlights that recombination is not just a background process but actively contributes to HIV's ability to adapt and potentially escape antibody neutralization, especially in the context of multilineage infections.
  • Timing and antibody levels matter: The data suggest that waning VRC01 levels between infusions might create windows of opportunity for co-acquisition of both sensitive and resistant viruses, and that lower predicted VRC01 concentrations at acquisition are associated with greater viral diversity.

Key Results

  • High frequency of multilineage infections: Approximately 38% of participants in both the African and Americas cohorts acquired HIV with multiple transmitted founder lineages (TFLs), a rate higher than previously reported in studies using less sensitive methods.
  • VRC01-discordant viruses are common: In 40% of multilineage infections, viruses with differing sensitivities to VRC01 (more than a 3-fold difference in IC80) were detected.
  • Sensitive lineages decline under VRC01 pressure: In six participants who acquired both sensitive and resistant viruses, the sensitive lineages declined over time, while resistant ones persisted.
  • Pervasive recombination: Recombination was observed in 63% of multilineage infections at the time of HIV diagnosis, and in one case, recombinant viruses preferentially inherited resistance mutations.
  • Association between VRC01 levels and viral diversity: Lower predicted VRC01 concentrations at the time of acquisition were associated with greater intra-participant variance in viral neutralization sensitivity.

Limitations and Future Work

  • Assumption of transmitted founder lineage: The study assumed that the viral sequence closest to the lineage-specific consensus best represented the transmitted founder. While supported by existing literature, they acknowledge this assumption could be violated by long periods between acquisition and sequencing or stochastic effects.
  • Limited sample size for specific analyses: While the overall study is well-powered, some analyses, particularly those looking at specific evolutionary events or the impact of VRC01 concentration, involved smaller numbers of participants.
  • Future directions: The authors suggest that future prevention strategies, similar to combination antiviral therapy, should target multiple viral antigens. Further research is needed to determine if combination bNAb therapy can reduce post-acquisition selection and to better define the role of recombination in HIV evolution under antibody pressure. The study also emphasizes the importance of maintaining consistently high monoclonal antibody levels in future prevention strategies.

Summary updated

Abstract

ABSTRACT In the HIV antibody mediated prevention (AMP) trials, the broadly neutralizing antibody VRC01 demonstrated protective efficacy against new diagnoses with susceptible HIV strains. To understand how VRC01 shaped breakthrough infections, we performed deep sequencing on 172 participants in the placebo and treatment arms, generating 63,444 gag-Δpol (2.5 kb) and 53,088 rev-env-Δnef (3 kb) sequences. Sequences were classified into transmitted founder lineages (TFLs), and infections with multiple distinct lineages were determined. Multilineage infections were detected in ∼38% of participants in both the African (HVTN 703/HPTN 081) and Americas/Europe (HVTN 704/HPTN 085) cohorts, regardless of placebo or treatment group, or cohort. The high levels of multilineage infections could be attributed to minor lineages (<5% abundance) identified in 20% of participants. Infection with VRC01 discordant viruses (IC80s >3-fold different) was observed in 40% of multilineage infections, with a trend toward greater intra-host neutralization differences with increasing VRC01 dose (Jonckheere-Terpstra test, p=0.072). In six VRC01 treated participants who acquired both sensitive (IC80<1µg/ml) and resistant viruses (IC80>3µg/ml), the sensitive lineages declined over time. Recombination was pervasive, observed in 63% of multilineage infections at the time of HIV diagnosis. In one treated participant infected with VRC01 discordant lineages, recombinant viruses preferentially inherited the resistance mutation (binomial p=0.004). In conclusion, our in-depth analysis of breakthrough viruses in the AMP trials revealed a high frequency of multilineage infections, including infections with viruses with different VRC01 sensitivities. This analysis also highlights the role of recombination in shaping intra-host viral evolution and facilitating escape from VRC01. Significance This work advances our understanding of the diversity of initial viral infection and evolution and in vivo activity of broadly neutralizing antibodies (bNAbs). Deep sequencing revealed ∼38% of HIV acquisitions with multiple transmitted founder lineages, higher than previous studies. These occurrences were similar in the placebo and VRC01 groups. Viral recombination among post-acquisition variants was common under antibody selection and appeared to favor resistant sequences in the treatment group. These data suggest as with single antiviral therapy, passive and active immunization of bNAbs should be directed at multiple antigen targets of HIV-1.
BibTeX
@misc{williamson2025influence,
  author = {Carolyn Williamson and Chivonne Moodley and Craig A. Magaret and Elena Giorgi and Morgane Rolland and Dylan H. Westfall and Anna Yssel and Wenjie Deng and Raabya Rossenkhan and Nonhlanhla N. Mkhize and Lennie Chen and Hong Zhao and Tanmoy Bhattacharya and Alec Pankow and Ben Murrell and Talita York and Asanda Gwashu-Nyangiwe and Nonkululeko Ndabambi and Ruwayhida Thebus and Paula Marantz Cohen and Bronwen E. Lambson and Haajira Kaldine and Sinethemba Bhebhe and Michal Juraska and Hongjun Bai and Allan C. deCamp and James P. Ludwig and Cindy Molitor and Nicolas Beaume and David Matten and Yunda Huang and Lily Zhang and Daniel B. Reeves and Bryan T. Mayer and Shelly Karuna and John Hural and Lynn Morris and David C. Montefiori and Roger E. Bumgarner and Penny L. Moore and Paul T. Edlefsen and Srilatha Edupuganti and Nyaradzo Mgodi and M. Juliana McElrath and Myron S. Cohen and Lawrence Corey and Peter B. Gilbert and James I. Mullins},
  title = {{Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials}},
  year = {2025},
  doi = {10.1101/2025.07.01.659979},
  howpublished = {bioRxiv},
}
Figure